血清微小RNA作为早期乳癌诊断标志物的价值

目的探讨血清5种微小RNA（miRNA）在乳癌早期诊断中作为生物标记物的价值。方法根据生物信息学数据库miRWalk的预测,选定5种与乳癌相关的miRNA（包括miR-31、miR-107、miR-155、miR-200c及miR-205）。采用实时荧光定量PCR检测5种miRNA在42例健康女性、66例乳癌病人中的相对表达量,根据受试者工作特征曲线（ROC曲线）下面积分析诊断乳癌的特异度和灵敏度。结果血清中miR-31、miR-107和miR-200c联合检测诊断乳癌的灵敏度为78.6%,特异度为88.7%。结论血清中miR-31、miR-107和miR-200c的组合有可能成为乳癌早期诊断的新指标。

THE VALUE OF SERUM MICRORNAS AS BIOMARKERS FOR EARLY DIAGNOSIS OF BREAST CANCER

Objective To assess the value of five serum microRNAs（miRNA）as biomarkers for early diagnosis of breast cancer. Methods According to bioinformatics database miRWalk prediction,five breast-cancer-related miRNAs（miR-31,miR-107,miR-155,miR-200 cand miR-205）were selected.The expressions of the five miRNAs in serum samples of 42 normal controls and 66 breast cancer patients were detected by real-time quantitative PCR.Specificity and sensitivity were analyzed by the areas under the receiver operating characteristic（ROC）curves of these miRNAs. Results The sensitivity and specificity of combined miR-31,miR-107 and miR-200 cfor breast cancer diagnosis were 78.6%and 88.7%,respectively. Conclusion The combination of serum miR-31,miR-107 and miR-200 cmay become a new marker for early diagnosis of breast cancer.